Actuate Therapeutics, Inc. Common stock (ACTU) Dividend History

Company News

• Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

  Actuate Therapeutics' Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival.

  GlobeNewswire Inc.
• Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

  Actuate Therapeutics, a clinical-stage biopharmaceutical company, will present data on its investigational drug elraglusib for the treatment of advanced salivary gland carcinoma at the AACR Annual Meeting 2025. The data suggests elraglusib in combination with chemotherapy and immunotherapy may be a promising approach for this rare and difficult-to-treat cancer type.

  GlobeNewswire Inc.
• Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

  Actuate Therapeutics and Lantern Pharma are collaborating to accelerate the development of Actuate's lead drug candidate, elraglusib, and enable the screening for additional biomarkers to assess and predict its therapeutic activity and clinical outcomes.

  GlobeNewswire Inc.

  Featured Companies: LTRN
• Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

  Actuate Therapeutics' elraglusib demonstrated anti-tumor activity with two ongoing complete responses and a 62% disease control rate in a Phase 1/2 trial for relapsed/refractory Ewing sarcoma. Enrollment is ongoing, with topline data anticipated in the first half of 2025.

  GlobeNewswire Inc.